ONCOLYTICS BIOTECH INC

Oncolytics Biotech Inc. announced it has secured a new U.S. patent from the USPTO, broadly protecting its proprietary manufacturing process for pelareorep. This patent is expected to provide intellectual property protection into 2044, supporting the company's ability to produce pelareorep at commercial scale. Additionally, a previously filed method-of-use patent application remains under review, potentially extending protection into 2046, and further patent filings are planned for 2026 to strengthen the IP portfolio.

Oncolytics Biotech Inc. announced the appointment of John McAdory as Chief Operating Officer, effective June 1, 2026. Mr. McAdory, previously the company's Executive Vice President, Strategy and Operations, will oversee clinical operations, development, and strategic partnerships. Additionally, Stephen Glover was appointed as the ninth director to the Board, bringing over 35 years of biopharmaceutical leadership experience, including guiding Ambrx Biopharma through its $2 billion acquisition. Both appointments are expected to strengthen the company's operational execution and strategic growth.

Oncolytics Biotech Inc. announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. Mr. Glover brings extensive public company leadership and transaction experience, including his role in the $2 billion acquisition of Ambrx Biopharma by Johnson & Johnson. Mr. McAdory, who joined Oncolytics earlier this year, will now oversee clinical operations, development, preclinical research, and strategic business development initiatives, aiming to accelerate the company's growth and advance its immunotherapy platform.

Oncolytics Biotech Inc. announced positive initial preclinical data for pelareorep in combination with RAS inhibitor modalities, demonstrating greater anti-tumor activity than individual approaches. Based on these findings, the company plans additional studies in pancreatic and colorectal cancer models to further evaluate immune activation, tumor response durability, and time-to-resistance. These results support pelareorep's potential as an immune-priming backbone for next-generation targeted therapies, particularly for difficult-to-treat RAS-mutated tumors.

Oncolytics Biotech announced initial preclinical data showing its investigational immunotherapy, pelareorep, combined with RAS inhibitor modalities, demonstrated greater anti-tumor activity in solid tumor models than individual approaches. These findings support pelareorep's role as an immune-priming backbone for next-generation targeted therapies, particularly for difficult-to-treat RAS-mutated pancreatic and colorectal cancers. The company plans further studies to evaluate immune activation, tumor response durability, and time-to-resistance, with full results expected in late 2026.

Oncolytics Biotech announced it will present positive translational data from its GOBLET and AWARE-1 clinical trials at the 2026 ASCO Annual Meeting. The data demonstrates that pelareorep, an investigational immunotherapy, expands pre-existing tumor-reactive immune cells and induces a multi-step immune activation process, including the expansion of mutant KRAS-specific T-cell clones. These findings correlate with tumor volume reductions in pancreatic cancer and support pelareorep's mechanism of action in difficult-to-treat cancers.

Oncolytics Biotech reported a widened net loss of $9.24 million for Q1 2026, compared to $4.71 million in Q1 2025, driven by increased operating expenses. The company also disclosed substantial doubt about its ability to continue as a going concern, as current cash resources are insufficient to fund operations for the next twelve months. To address liquidity, the company utilized an at-the-market offering, raising $7.61 million in net proceeds during the quarter, and entered into a new ATM agreement post-period.

Oncolytics Biotech Inc. announced new durability data from its REO 022 study in metastatic colorectal cancer, demonstrating a 19.5-month median duration of response in second-line KRAS-mutant MSS mCRC patients. This represents a significant 3-4x improvement over historical benchmarks. The pelareorep-based combination therapy also achieved a 33% objective response rate, tripling the standard of care. The company is actively engaging with the FDA to discuss a potential accelerated approval pathway based on these compelling results.

Oncolytics Biotech, Inc. announced it has achieved alignment with the U.S. Food and Drug Administration on plans for a controlled randomized pivotal study. This study will focus on squamous cell carcinoma of the anal canal, marking a significant step forward in the company's clinical development program.

Oncolytics Biotech announced alignment with the U.S. Food and Drug Administration (FDA) on the design of a pivotal clinical study for pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal (SCAC). The study will be a randomized controlled trial, aiming to support both accelerated and full approval within the same study. This development provides an efficient pathway for pelareorep in a disease with significant unmet medical need, leveraging strong durability and survival data from previous studies.